Skip to content


Nulojix (belatacept) is a protein pharmaceutical. Belatacept was first approved as Nulojix on 2011-06-15. It has been approved in Europe to treat graft rejection and kidney transplantation. The pharmaceutical is active against T-lymphocyte activation antigen CD80 and T-lymphocyte activation antigen CD86.
Trade Name Nulojix
Common Name Belatacept
Indication graft rejection, kidney transplantation
Drug Class Receptor molecules, native or modified: T-cells
Get full access now